US Patent

US9006289 — Levothyroxine formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2032-10-03 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a levothyroxine composition that includes levothyroxine sodium and mannitol in a solid form.

USPTO Abstract

A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.

Drugs covered by this patent

Patent Metadata

Patent number
US9006289
Jurisdiction
US
Classification
Formulation
Expires
2032-10-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.